treatment

The company said it could not find enough test patients in its Phase Ib clinical trial for the last six months. The disease afflicts mainly children.

StemCells Inc. (STEM) is down just over 9% but it is paring losses from its opening bell skid to 73 cents, sparked by the company's announcement that it is ending its program for a stem-cell treatment for Batten disease.

Health care shares are trending higher, while Abbott Laboratories (ABT) is seeing solid gains after reporting study results. In sector news, Abbott Laboratories (ABT) today announced that data from its Endovascular Valve Edge-to-E

Each stock option has an exercise price per share equal to $11.83, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commenceme

Optimer Pharmaceuticals (OPTR) says that on March 31, its Board approved the grant of inducement stock options to purchase an aggregate of 258,000 shares of common stock to 7 new employees.

Kevin Buchi, Chief Executive Officer of Cephalon, said, "The proposed transaction allows ChemGenex shareholders to realize cash proceeds at a significant premium to recent trading levels and adds an interesting late-stage opportun

The deal will give the company a potential leukemia treatment and is Cephalon's seventh acquisition in the past year.

Cephalon Inc. (NASDAQ:CEPH) agreed to buy ChemGenex Pharmaceuticals Ltd. for A$225 million in cash, according to a Bloomberg report.

Health care shares are lower in mid-session trading while Xoma (XOMA) tumbles after disappointing results from a clinical trial. The company is down nearly 30% in early trading, after it said late Tuesday its Phase 2b trial of XOM

The company has an unapproved drug, Protectan, which has so far shown to be effective in treating radiation sickness up to 48 hours after the initial exposure.

Chief Executive Michael Fonstein said Monday, "There are no approved drugs in this area, and we definitely believe we have a very potent remedy. Obviously, our drug is highly relevant. However, it is unlicensed.

Shares of Cleveland BioLabs (NASDAQ:CBLI) jumped sharply for the second day in a row, and are now trading up over 20% from its closing price just this past Friday.

Health care shares are down in mid-day trading, but Human Genome Sciences (HGSI) bucks the trend, after getting a key approval from the U.S. Food and Drug Administration. the FDA approved BENLYSTA to treat adult patients with acti

Dr. Barry Polisky, Chief Scientific Officer at Marina, said in a statement: "These results further demonstrate the utility of our DiLA2 delivery technology for local administration."

Marina Biotech shares are up 7.47%, to $0.731.

Shares of Marina Biotech (MRNA) are higher after company data was presented demonstrating significant knockdown of target mRNA in an orthotopic model of malignant ascites with its proprietary UsiRNA construct and DiLA2-based deliv

Health care shares are higher Monday. Bloomberg is reporting that a high school teacher in Tasmania is suing Johnson & Johnson over an implanted hip-replacement device that stopped selling in Australia due to defects. Meanwhil

Salix is plunging 22% in pre-market trade, after announcing that based on a telephone conversation with the U.S. FDA held last evening, the company anticipates receiving a Complete Response Letter on or before March 7. That's the

Healthcare stocks show mixed direction this morning. But some big declines are seen from Salix Pharmaceuticals, Ltd. (SLXP) and HeartWare International, Inc. (HTWR)